Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS)

Abdelhady, Enas I.; Rabie, Mona; Hassan, Rofaida A.

doi:10.1007/s10067-021-05803-7

Cited by 13 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study revealed that >70% of the patients with SLE had moderate-severe disease activity, which may be related to the fact that our study population was all inpatients; therefore, the correlation between SLE-DAS and SLEDAI 2000 was not very strong (rho=0.709) but acceptable, which was generally consistent with several recent studies. 25 26 A cross-sectional study conducted on 117 patients with SLE revealed a correlation coefficient of 0.743 between SLE-DAS and SLEDAI 2000. 25 Additionally, a prospective cohort study of 333 patients with SLE in Taiwan revealed a correlation coefficient of 0.78 between SLE-DAS and SLEDAI 2000.…”

Section: Discussionmentioning

confidence: 99%

“… 25 26 A cross-sectional study conducted on 117 patients with SLE revealed a correlation coefficient of 0.743 between SLE-DAS and SLEDAI 2000. 25 Additionally, a prospective cohort study of 333 patients with SLE in Taiwan revealed a correlation coefficient of 0.78 between SLE-DAS and SLEDAI 2000. 26 However, the present study demonstrated that the correlation and agreement between the disease activity grading of the two scoring criteria was not satisfactory, and more studies are required to confirm this result in the future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study

Ma,

Zhang,

Yan

et al. 2024

Lupus Sci Med

View full text Add to dashboard Cite

ObjectivesThis study aimed to evaluate the clinical value of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) for assessing disease activity in patients with SLE.MethodsClinical data were collected from patients with SLE who were admitted at the Second Affiliated Hospital of Soochow University from January 2009 to December 2022. The glucocorticoid dose grading was used as the gold standard for disease activity assessment in SLE. The SLE-DAS value was calculated, and the SLE disease activity status was graded based on the SLE-DAS value. Another scoring criterion, the SLE Disease Activity Index 2000 (SLEDAI 2000), served as a control. Spearman correlation analysis was used to calculate the correlation between the scoring criteria and other variables.ResultsThe analysis included 396 patients with SLE. A strong correlation was found between SLE-DAS and SLEDAI 2000 (ρ=0.709, 95% CI 0.648 to 0.766, p<0.001), with median SLE-DAS and SLEDAI 2000 scores of 15.32 (7.90 to 24.45) and 13 (8 to 19), respectively. Compared with the SLEDAI 2000 value, the SLE-DAS value correlated better with glucocorticoid dose grading (ρ=0.434 vs 0.518), gammaglobulin use (ρ=0.170 vs 0.318) and immunosuppressant use (ρ=0.122 vs 0.221). A moderate correlation based on disease activity grading was found between SLE-DAS and glucocorticoid dose grading (ρ=0.441), whereas a mild correlation was observed between SLEDAI 2000 and glucocorticoid dose grading (ρ=0.325). Additionally, SLE-DAS revealed a positive correlation with severe thrombocytopenia, cardiac involvement and pulmonary involvement but not SLEDAI 2000.ConclusionCompared with SLEDAI 2000, SLE-DAS may provide a more accurate disease activity assessment in patients with SLE, especially those with severe thrombocytopenia and cardiopulmonary involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study

Ma,

Zhang,

Yan

et al. 2024

Lupus Sci Med

View full text Add to dashboard Cite

show abstract

“…Previous studies determined that a total SLE‐DAS score of ≤2.08 represents remission; 2.09–3.77 represents low disease activity; 3.78–7.64 represents mild disease activity; and 7.65 or more represents moderate/severe disease activity (Jesus, Matos, Henriques, Zen, Larosa, Iaccarino, da Silva, et al 2019; Jesus, Matos, Henriques, Zen, Larosa, Iaccarino, Doria, Inês, 2019). The SLE‐DAS has established acceptable reliability and validity in Caucasian, African American, Asian, and Hispanic populations (Abdelhady et al, 2021; Hsu et al, 2022; Jesus et al, 2021).…”

Section: Methodsmentioning

confidence: 99%

Effects of a walking exercise programme on disease activity, sleep quality, and quality of life in systemic lupus erythematosus patients

Lin

Livneh

et al. 2023

Int J of Nursing Practice

View full text Add to dashboard Cite

AimThis quasi‐experimental study aimed to explore effects of walking exercise on disease activity, sleep quality, and quality of life among individuals with systemic lupus erythematosus.MethodsAfter recruiting people with systemic lupus erythematosus from a hospital in Taiwan between October 2020 and June 2021, participants were free to opt to receive one walking exercise programme plus standard care for 3 months or to membership of a control group receiving routine care. Primary outcomes included Systemic Lupus Erythematosus Disease Activity Score, the Pittsburgh Sleep Quality Scale, and a quality‐of‐life scale for patients with systemic lupus erythematosus, namely, LupusQoL. These scales were administered first, at baseline and later, within 1 week following completion of the intervention. Between‐group effects were compared using generalized estimating equations with adjustment for baseline variables.ResultsThe experimental and control groups each included 40 participants. Multivariate analysis indicated that adding the walking exercise programme into routine care elevated sleep quality and LupusQoL (the latter in the subscales of physical health, planning, and intimate relationships), except for disease activity.ConclusionFindings of this study supported the addition of walking exercise as part of routine care for people with systemic lupus erythematosus and may be a reference in the provision of adequate care for these patients.

show abstract

“…However, measuring LLDAS in routine clinical settings can be challenging. Abdelhady et al showed a good agreement between SLEDAI-2K-derived LLDAS and SLE-DAS in a study of 117 patients with SLE [44]. Assunção et al found that SLE-DAS LDA (defined as SLE-DAS ≤ 2.48 and a daily prednisone dose or its equivalent ≤ 7.5 mg) correlated well with SLEDAI-2K-derived LLDAS in a study involving 774 patients with SLE, with 300 in the derivation cohort and 474 in the validation cohort [45].…”

Section: Sle-das As a Treatment Target For Slementioning

confidence: 97%

Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS

Koo,

2023

Medicina

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that affects multiple organ systems and manifests in a relapsing–remitting pattern. Consequently, it is paramount for rheumatologists to assess disease activity, identify flare-ups, and establish treatment goals for patients with SLE. In 2019, the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) was introduced as a novel tool for measuring disease activity. This tool refines the parameters of the established SLE Disease Activity Index 2000 (SLEDAI-2K) to enhance the assessment process. This review aims to provide an introduction to the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) and summarizes research on its development, its comparison with existing disease activity measures, and its performance in clinical settings. Literature searches on PubMed using the keyword “SLE-DAS” were conducted, covering publications from March 2019 to September 2023. Studies that compared SLE-DAS with other SLE disease activity measurement tools were reviewed. Findings indicated that SLE-DAS consistently performs on par with, and sometimes better than, traditional measures in assessing clinically meaningful changes, patient improvement, disease activity, health-related quality of life, hospitalization rates, and disease flare-ups. The association between SLE-DAS and mortality rates among patients with SLE, however, remains to be further explored. Although SLE-DAS is a promising and potentially effective tool for measuring SLE disease activity, additional research is needed to confirm its effectiveness and broaden its clinical use.

show abstract

Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS)

Cited by 13 publications

References 11 publications

Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study

Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study

Effects of a walking exercise programme on disease activity, sleep quality, and quality of life in systemic lupus erythematosus patients

Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS

Contact Info

Product

Resources

About